2 news items
U.S. Medicines Spending Grew in 2023 as Greater Access Offset COVID-19-related Decline, Says IQVIA Institute
IQV
14 May 24
of GIP/GLP-1 agonists, which are approved and widely reimbursed for diabetes but are less commonly covered for obesity
IQVIA Reports First-Quarter 2024 Results
IQV
2 May 24
reimbursed expenses, was $30.1 billion, growing 7.9 percent year-over-year and 8.3 percent at constant currency. The company expects approximately $7.7
- Prev
- 1
- Next